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ABSTRACT
Objectives: To describe the health-related quality of life (HRQOL) impli-
cations of hypoactive sexual desire disorder (HSDD) in a national sample
of postmenopausal women ages 30–70.
Methods: The Nationwide Survey of Female Sexual Health, a random-
digit telephone survey of US households, collected information on female
sexual function, demographic characteristics, HRQOL, and the presence
of speciﬁc medical disorders from 1189 naturally or surgically postmeno-
pausal women in stable relationships of 3 months duration. HSDD was
deﬁned as <40 on the Proﬁle of Female Sexual Function© scale and <60
on the Personal Distress Scale©. Short Form-12 Health Survey (SF-12)
summary and domain scores, and EuroQol (EQ-5D) index score and
dimensions were compared with population-based norms for healthy indi-
viduals and selected chronic conditions.
Results: HSDD was associated with signiﬁcant HRQOL decrements,
with the largest SF-12 score differences in mental health (HSDD:
45.4 [standard error 1.9] vs. no HSDD: 51.0 [0.6], P < 0.01), vitality
(HSDD: 47.7 [1.3] vs. no HSDD: 52.0 [0.7], P < 0.01), social func-
tion (HSDD: 47.3 [1.4] vs. no HSDD: 50.9 [0.7], P < 0.05), and bodily
pain (HSDD: 41.4 [2.2] vs. no HSDD: 46.7 [0.9], P < 0.05). EQ-5D index
was 0.08 points lower (HSDD: 0.76 [0.03] vs. no HSDD: 0.84 [0.02],
P < 0.05) for those with HSDD compared with those without. HSDD was
associated with a 0.1-point decrement in naturally menopausal women
(HSDD: 0.78 [0.03] vs. no HSDD 0.88 [0.01], P < 0.01). Women with
HSDD showed more HRQOL impairment than healthy population norms
but were similar to adults with other chronic conditions such as diabetes
and back pain.
Conclusions: Women with HSDD showed substantial impairment in
HRQOL. Given a prevalence of 6.6% to 12.5% among US women, HSDD
represents an important burden on quality of life.
Keywords: health-related quality of life, hypoactive sexual desire
disorder, menopause, Proﬁle of Female Sexual Function (PFSF©), sexual
dysfunction.
Introduction
Hypoactive sexual desire disorder (HSDD) is deﬁned as the
persistent lack of sexual desire causing “marked stress or inter-
personal difﬁculties” as described in the Fourth Edition of the
Diagnostic and Statistical Manual of Mental Disorders (DSM-
IV) [1]. This deﬁnition, based on the model of sexual response
posed by Masters and Johnson [2] and Kaplan [3] focuses on
sexual thoughts and fantasies and assumes that desire occurs
before initiating sexual intercourse and between experiences of
sexual intercourse [4]. Recent guidelines have further reﬁned the
deﬁnition of HSDD [4–6], taking into account “the inability to
access any desire during the experience (emphasis in original),”
and considering lessening in desire beyond what would normally
be expected across the life cycle and with relationship duration
[4,6]. Only a few researchers have undertaken studies to deter-
mine the prevalence of HSDD among women in the United States
[7,8] and Western Europe [9], reporting prevalence ranging from
7% to 26%. Variations in reported prevalence are associated
with differences in the populations studied (national vs. commu-
nity vs. clinic), data collection approach, deﬁnition of sexual
dysfunction and desire disorder, and period of observation [10].
Furthermore, a few studies have suggested that the preva-
lence of HSDD is higher among surgically menopausal women
[8,9,11]. A recent study by Leiblum and colleagues [8] reported
results from US women in the Women’s International Study on
Health and Sexuality (WISHeS) showing that the prevalence of
HSDD ranges from 9% to 26% depending upon the woman’s
current age and her menopausal status. Speciﬁcally, they found
that younger surgically menopausal women were at highest risk
for HSDD. This ﬁnding was further supported by the European
arm of the study by Dennerstein and colleagues which also
reported the highest prevalence of HSDD, 16%, among the
younger population of surgically menopausal women [9]. A
recent, nationally representative prevalence study (the Nation-
wide Survey of Female Health) by West and colleagues [11]
conﬁrms these results, reporting HSDD prevalence ranging from
6.6% to 12.5%, with surgically menopausal women at highest
risk. Although HSDD is classiﬁed by the DSM-IV as a disorder,
some questions still exist whether this condition represents a
signiﬁcant and clinically relevant problem for women or whether
it represents a disorder that has become “medicalised” because
of its pharmaceutical market potential [4,6,7,12–17]. This skep-
ticism suggests the need for evidence on the effects of HSDD on
health status and health-related quality of life (HRQOL). That is,
does HSDD affect a signiﬁcant number of women (and does
it target some women disproportionately) and what effect does
it have on relationships, quality of life, and social interaction?
Recently, Leiblum and colleagues [8] reported preliminary
health status data from the WISHeS study using the Medical
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Outcomes Study Short Form (SF)-36. They found that women
with HSDD experienced large and statistically signiﬁcant decre-
ments in health status, with much larger decrements on domains
that measure aspects of mental health status (i.e., MH,
social functioning [SF], vitality [VT], and emotional role fulﬁll-
ment). Nevertheless, they did not report data by menopausal
status. Women who have undergone surgical menopause, as
opposed to those who progress through menopause naturally,
experience abrupt and dramatic declines in hormones that may
be associated with more dramatic declines in libido and may
result in sexual dysfunction [18]. The resulting dysfunction has
been shown to be related to problems of mood, self-esteem, and
emotional distress [5], which may translate into lower quality
of life.
To our knowledge, no other study reports HRQOL data for
this group of surgically and naturally postmenopausal women.
Using the groundwork laid by Leiblum and colleagues [8], we
present here a systematic and detailed description of the health
burden and HRQOL among women with HSDD. We use a
nationally representative sample of US women ages 30 through
70, and well-validated instruments to assess the burden and to
systematically evaluate the relationship between HSDD and
health status and HRQOL. We also compare our results with
national norms, allowing us to place HSDD into context with
other common disorders and to add to the growing catalogue of
national preference scores available for use in cost-effectiveness
analyses [19,20].
Methods
Data Source
The Nationwide Survey of Female Sexual Health collected infor-
mation on female sexual function and factors that were hypoth-
esized to affect function. Data were collected between September
9, 2004 and March 30, 2005, from a total of 2207 women
(weighted response rate 56.7% [21]). Detailed discussion of the
study methods is provided elsewhere [11].
Brieﬂy, women ages 30 to 70 were selected from a national
sample of households using a dual-frame probability sampling
approach. One-tenth of the sample was selected from a random
digit-dialing frame, while the remainder came from a frame of
telephone directory-listed residential telephone lines for which
recent demographic data were available. Women were eligible to
participate if they were between the ages of 30 years and 70
years, inclusive, were involved in a stable sexual relationship
of at least 3 months duration, and either had both ovaries or
no ovaries at all (i.e., they were bilaterally oophorectomized).
Computer-assisted telephone interview technology was used by
female interviewers to collect information on demographic char-
acteristics, smoking and alcohol use, the presence and treatment
of speciﬁc medical disorders, female sexual dysfunction, family
stress, satisfaction with relationships, and burden of illness
including quality of life and medical resource use. Informed
consent was obtained from the women, and ethics approval was
obtained from the Ofﬁce of Human Research Ethics at the Uni-
versity of North Carolina at Chapel Hill. The survey data were
collected by the Survey Research Unit at the University of North
Carolina at Chapel Hill.
Description of Instruments
Four well-validated instruments were used as part of the survey
questionnaire: the Proﬁle of Female Sexual Function© (PFSF©),
Personal Distress Scale© (PDS©), the Short Form-12 Health
Survey (SF-12) version 2, and the EuroQol descriptive system
(EQ-5D).
Developed by Procter & Gamble Pharmaceuticals (Mason,
OH), the PFSF is a 37-item questionnaire that measures various
aspects of sexual function. Seven individual domains of sexual
function include: sexual desire, sexual pleasure, sexual arousal,
orgasm, sexual responsiveness, sexual concerns, and sexual self-
image. Women responded to questions on a scale from 1 (always)
to 6 (never). Additionally, one item assesses overall sexual satis-
faction. Originally developed and validated with postmeno-
pausal women [22,23], the PFSF also has been used in several
clinical trials [24–27] and population surveys [8,9]. The seven-
item PDS© [28] was used to measure distress caused by low
sexual desire. High scores from the PDS instrument represent
greater distress, whereas for the PFSF instrument, higher scores
represent better sexual function status. The PFSF© and PDS
scores were calculated according to the methodology described
by Dennerstein and colleagues [9].
We measured health status and HRQOL using two previously
validated instruments, the SF-12 v.2, and the EQ-5D, respec-
tively. The SF-12 is a 12-item generic health status questionnaire
that was derived from the longer and widely used SF-36 and is
used in situations where a more concise survey is desirable [29].
Head-to-head comparisons of the instruments suggest that the
SF-12 is most appropriate for population-based surveys such as
ours [30,31]. As with the SF-36, the SF-12 is composed of eight
domains (physical functioning [PF], role physical [RP], role emo-
tional [RE], bodily pain [BP], general health [GH], MH, VT, and
SF) and two summary scores (physical component summary
[PCS-12] and mental component summary [MCS-12]) [29]. All
scores are reported on a scale from 0 to 100, with higher scores
representing better health. We employed the algorithms of Ware
and colleagues [29] to combine data from the individual items
into the eight individual domain scales. Norm-based scores sub-
sequently were constructed and the two summary measures were
constructed using Ware and colleagues’ [29] algorithm and the
1998 US general population means and standard deviations (SD).
The mean and SD for the normed MCS-12, PCS-12, and indi-
vidual domain scores are 50 and 10, respectively. Norm-based
scores are critical to meaningful comparisons between the scales
and the summary measures, and allow comparison between dif-
ferent health conditions; scale scores less than 50 indicate that
health status is below average.
The EQ-5D is a 5-item descriptive system measuring health
status along ﬁve dimensions (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression). The EQ-5D has been
used widely for clinical trials, economic studies, and population
health surveys worldwide, resulting in more than 800 publi-
cations through June 2004 [32]. Using the EQ-5D, women
rated their own difﬁculty for each dimension as no problems,
some problems, or severe problems. All possible combinations of
dimensions and levels result in 243 unique health states. Previous
studies have developed multi-attribute utility functions (i.e.,
scoring algorithms) to assign preference weightings or utilities to
each of these health states [33,34]. Preference weighting repre-
sents individual desire for or value for particular health states.
Over the past several decades, preference weightings, like those
from the EQ-5D, have been used to adjust survival for quality of
life in cost-effectiveness analyses [35]. These scoring algorithms
are used to calculate the EQ-5D index score from the responses
to the ﬁve-item questionnaire. The US preference weighting
system developed by Shaw and colleagues [34] was used to
estimate the index score for the women involved in this study.
Scores ranged from negative values (i.e., states worse than death)
to 1 (perfect health). We report the index as well as the
proportion of women experiencing limitations in each of the
dimensions.
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SF-12 scores are available for the general population, by age
and sex, for “healthy” individuals (i.e., individuals without any
chronic diseases), and for various chronic conditions [29,36].
Ware and colleagues [29] provide norms by age, sex, and for
various chronic conditions in the general US population based on
a national postal survey conducted between October and Decem-
ber 1998. Sampling weights were adjusted using 1998 US Census
data to match age, sex, and the age-within-sex distribution.
Hanmer and colleagues [36] use data from the 2000 Medical
Expenditure Panel Survey (MEPS) to establish national age-
stratiﬁed and gender-stratiﬁed norms for several preference and
non-preference-based HRQOLmeasures including the SF-12 and
EQ-5D. EQ-5D index scores were compared with US values
[19,36,37]. Sullivan and Ghushchyan [37] report EQ-5D values
by clinical diagnoses derived from the 2000–2002 MEPS as part
of a catalogue of nationally representative, community-based
preferences.
We compared SF-12 and EQ-5D scores for women with and
without HSDD with those of healthy individuals and individuals
with other chronic conditions, including diabetes and back pain.
These conditions were chosen because they have a major impact
on physical and emotional function.
Depression and Antidepressant Use
Depression was measured using the Center for Epidemiologic
Studies Depression Scale (CES-D-8), with women reporting a
score of 8 or more identiﬁed as depressed [38]. Antidepressant
use was based on a woman’s self-report of current use of these
medications for the treatment of depression.
Menopausal and Hypoactive Sexual Desire
Disorder Classiﬁcations
Menopausal status was classiﬁed into one of four categories:
premenopausal, perimenopausal, naturally menopausal, and sur-
gically menopausal. Self-reported information on timing of last
menstrual period, recent or current pregnancy, reproductive
surgeries (bilateral oophorectomy or hysterectomy), hormone
use, and age were used in the classiﬁcation process; details of this
algorithm are provided elsewhere [11]. For the purposes of these
analyses, we examine only women who have undergone natural
(n = 552) or surgical (n = 637) menopause, where surgical meno-
pause was deﬁned as bilateral oophorectomy with or without
a hysterectomy. We excluded 636 premenopausal women, 206
perimenopausal women, 24 pregnant women, and 33 women
with unknown pregnancy or menopausal status.
HSDD is characterized by low sexual desire with concomitant
personal distress resulting from low sexual desire [1,4,5,7]. We
used clinically validated thresholds for desire and distress using
the PFSF and PDS, respectively [22,23,28]. As such, we deﬁned
HSDD as a PFSF desire domain score <40 and a PDS© score <60;
women meeting these criteria would have indicated that,
on average, they “seldom” or “never” felt sexual desire and
experienced signiﬁcant concern or distress about this lack of
sexual desire.
Comorbidities
The women were asked whether a physician or health profes-
sional had ever told them that they had one of the following 23
comorbidities—heart disease, high blood pressure, high choles-
terol, stroke or transient ischemic attack, heart attack, arthritis
or joint pain, depression, diabetes, obesity, polycystic ovary syn-
drome, thyroid problems, urinary incontinence, osteoporosis,
cancer (other than breast or cervical), noncancerous breast
lumps, breast cancer, cervical cancer, headaches or migraines,
fatigue, back pain, insomnia or sleep disturbances, memory
problems, or loss of sexual desire. These conditions were selected
for query because low levels of estrogen and/or testosterone may
inﬂuence their occurrence, either by their potential mutagenicity,
altering a women’s cardiovascular or neurotransmitter proﬁle,
or affecting other interrelated factors. Data are not presented
for comorbidities for which the observed prevalence was not
signiﬁcantly different from zero.
Statistical Analysis
Means, proportions, and associated standard errors are reported
for continuous and categorical variables. Student’s t-test and
analysis of variance were employed to evaluate mean differences
between the menopausal and HSDD groups and to compare
survey means to published norms. The Rao–Scott design-
adjusted chi-square test [39–41] was used to evaluate differences
in categorical outcomes among the groups.
To examine factors predicting health status and HRQOL, we
conducted survey-weighted regression analysis using the EQ-5D
index and the SF-12 physical and mental component summary
scores, respectively, as the dependent variables. Menopausal
status and the presence of HSDD were the independent variables
of interest. To test the combined effects of HSDD and meno-
pausal status and/or depression, we included interaction terms;
nonsigniﬁcant interaction terms were subsequently deleted from
the model speciﬁcation. The presence of comorbid conditions
and demographic characteristics, including age, race/ethnicity,
marital status, income, educational attainment, and obesity were
included to control for factors previously shown to be associated
with HSDD [10]. Three variables capturing family stress and
physical and emotional satisfaction with the current sexual
partner were added to evaluate the effects of relationships on
health status and perceived quality of life [42].
All analyses were conducted using SAS statistical software,
version 9.1 (SAS Institute, Cary, NC). Survey procedures were
employed to correct for the complex sampling design. Subgroup
analyses were adjusted for variation that may be unrelated to
the survey sampling process [43]. Differences are considered
statistically signiﬁcant if the P-value is less than 0.05, and cor-
rections are not made for multiple comparisons.
Results
A total of 1189 naturally and surgically postmenopausal women
completed the survey (Table 1). On average, our respondents
were 57 years old, 87% were white, and 81% were married or
living with a partner. Nearly 61% had less than a college educa-
tion, with approximately 16% having a high school diploma or
less. Slightly more than 9% reported HSDD. Based on the CES-
D-8 administered during the interview, 11% of the postmeno-
pausal women exhibited depressive symptoms. Regardless of
symptomatology, about 15% of the postmenopausal women
included in our study were treated for depression. In total, 98%
of women reported at least one comorbidity, with a mean of 5.2
(standard error [SE] = 0.2) conditions. Nearly 10% of the
women reported 10 or more comorbidities with a maximum of
16 conditions reported.
Compared with women without HSDD, women with HSDD
were more likely to be depressed, whether or not they reported
current antidepressant use (P = 0.006), and to express dissatis-
faction with their home life (P = 0.039) and with the emotional
(P = 0.002) and physical (P < 0.001) relationships with their
sexual partner. They also were slightly younger although the
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difference fell just short of statistical signiﬁcance (P = 0.059).
Surgically menopausal women were slightly more likely to report
HSDD than naturally menopausal women (12.5% vs. 6.6%,
P = 0.059). Women with HSDD reported signiﬁcantly more
comorbidities than women without HSDD (P < 0.001). They
were signiﬁcantly more likely to report back pain (P = 0.022),
fatigue (P < 0.001), memory problems (P = 0.018), and depres-
sion (P = 0.012). For each of these conditions, women with
HSDD were nearly twice as likely to report the condition as
women without HSDD. They also were more likely to report
insomnia and migraines or headache, though these differences
had borderline statistical signiﬁcance.
Several of these differences remained after we accounted for
menopausal status (i.e., surgical vs. natural). Among surgically
menopausal women, those with HSDD were more likely to
report symptoms of depression (P = 0.032), and to be less satis-
ﬁed with home life in general (P = 0.049), and with their emo-
tional (P < 0.001) and physical (P < 0.001) relationships with
their primary partner. Naturally menopausal women with HSDD
were more likely to have depressive symptoms with or without
antidepressant treatment (P = 0.005) than those without HSDD.
Regardless of menopausal status, women with HSDD were more
likely to report comorbidities than women without; however,
differences attained statistical signiﬁcance only for fatigue (sur-
gically menopausal women, P = 0.003) and depression (naturally
menopausal women, P = 0.008). Although there were some dif-
ferences between naturally menopausal women with and without
HSDD in terms of their satisfaction with home life, and emo-
tional and physical relationships with their partners, none of
these reached statistical signiﬁcance.
Health Status and Health-Related Quality of Life
There were substantial differences between women with and
without HSDD in health status and HRQOL as measured
by the SF-12 (summary and domain scores) and EQ-5D (index
and individual dimensions) instruments (Tables 2 and 3, respec-
tively). Women with HSDD reported poorer health status
as evidenced by lower SF-12 summary and domain scores
(Table 2). Statistically signiﬁcant differences were observed for
the mental summary score (P = 0.033), and the BP (P = 0.025),
MH (P = 0.006), VT (P = 0.004), and SF (P = 0.025) domain
scores. These differences suggest that women with HSDD
experience substantial decrements to their health status and
HRQOL.
When we disaggregate by menopausal status, this disparity in
health status persists. Surgically menopausal women with HSDD
reported lower scores across all measures with the differences
in the MCS-12 (P = 0.011), GH (P = 0.027), MH (P =
0.016), and VT (P = 0.026) scores attaining statistical signiﬁ-
cance. A similar pattern was observed for naturally menopausal
women with HSDD who reported signiﬁcantly more pain than
their counterparts without HSDD (P = 0.027).
Women with HSDD reported lower EQ-5D index scores than
women without HSDD (0.76 vs. 0.84, P < 0.010) (Table 3). They
also were more likely to report difﬁculties for each of the ﬁve
dimensions although only two dimensions were statistically dif-
ferent: pain and discomfort (P = 0.017) and anxiety and depres-
sion (P < 0.001). Among naturally menopausal women, those
with HSDD reported lower EQ-5D index scores (P = 0.002) and
more difﬁculty with self-care (P < 0.001) and more anxiety
and depression (P = 0.006) compared with their counterparts
without HSDD.
Factors predicting EQ-5D index and SF-12 physical and
mental summary scores are presented in Table 4. After con-
trolling for several factors, both HSDD and surgical menopause
were associated with lower EQ-5D index scores. Only surgical
menopause was associated with lower HRQOL as measured by
PCS-12 scores. Neither HSDD nor surgical menopause predicted
MCS-12 scores, which were predicted primarily by current
Table 1 Comparison of demographic and clinical characteristics‡ of
postmenopausal women by HSDD status (n = 1189)
Characteristic All HSDD No HSDD
Mean age, years 56.9 (0.6) 54.0 (1.3) 57.2 (0.7)
Age category (%)
30–39 2.0 (0.6) 4.6 (1.9) 1.8 (0.6)
40–49 14.9 (2.6) 21.5 (5.6) 14.3 (2.9)
50–59 43.5 (3.0) 48.7 (7.8) 43.0 (3.2)
60–70 39.5 (3.1) 25.2 (9.3) 40.9 (3.4)
Menopausal status (%)
Surgical§ 42.4 (3.3) 58.3 (8.4) 40.8 (3.6)
Natural 57.6 (3.3) 41.7 (8.4) 59.1 (3.6)
Race/ethnicity (%)
White, non-Hispanic 86.9 (2.1) 89.9 (4.3) 86.6 (2.3)
Black, non-Hispanic 6.4 (1.5) 8.1 (4.2) 6.2 (1.6)
Hispanic 4.4 (1.4) 0.23 (0.15) 4.8 (1.6)
Other/multiracial 2.3 (0.7) 1.7 (0.9) 2.3 (0.8)
Educational attainment (%)
<High school or high school
diploma
15.9 (2.2) 15.3 (4.2) 16.0 (2.4)
Vocational/2-year degree 44.8 (3.5) 54.2 (7.7) 43.8 (3.8)
4-year college degree 24.3 (3.1) 22.0 (5.8) 24.5 (3.4)
Graduate degree 15.0 (2.3) 8.4 (5.4) 15.7 (2.4)
Married or living together (%) 81.2 (3.1) 89.7 (4.2) 80.4 (3.3)
Income $60,000 (%) 53.7 (3.6) 48.3 (8.2) 54.2 (3.8)
Body mass index (%)
<25 39.2 (3.4) 27.4 (5.7) 40.4 (3.7)
25-<30 29.2 (3.1) 41.0 (7.9) 28.0 (3.3)
30+ 31.5 (3.4) 31.6 (8.4) 31.5 (3.7)
Reported comorbidity† (%)
Fatigue 41.4 (3.4) 67.5 (7.2)*** 38.8 (3.6)
Back pain 43.2 (3.4) 60.9 (7.6)* 41.5 (3.6)
Arthritis or joint pain 55.1 (3.4) 55.9 (7.7) 55.0 (3.7)
Insomnia 39.4 (3.2) 54.3 (8.1) 37.9 (3.6)
Memory problems 28.6 (3.1) 46.1 (8.0)* 26.9 (3.3)
Depression 26.2 (2.8) 43.5 (7.6)* 24.5 (7.6)
Current depressive symptoms and
antidepressant use (%)
Symptomatic and treated 4.3 (0.9) 9.0 (2.3)** 3.8 (6.0)
Symptomatic and untreated 6.6 (1.6) 16.1 (5.2) 5.6 (1.7)
No symptoms and treated 11.4 (2.2) 16.7 (6.2) 10.8 (2.3)
No symptoms and not treated 77.8 (2.7) 58.0 (7.6) 79.7 (2.9)
Satisfaction with home life (%)
Very satisﬁed 63.0 (3.4) 44.0 (8.1)* 64.8 (3.6)
Somewhat satisﬁed 28.2 (3.2) 38.0 (7.6) 27.2 (3.4)
Somewhat dissatisﬁed 6.8 (1.6) 13.8 (4.7) 6.1 (1.6)
Very dissatisﬁed 2.0 (0.6) 4.2 (2.6) 1.8 (0.7)
Satisfaction with emotional
relationship with partner (%)
Very satisﬁed 63.6 (3.2) 41.6 (8.2)** 65.8 (3.4)
Somewhat satisﬁed 23.4 (2.6) 38.2 (7.4) 21.9 (2.8)
Neither 2.8 (1.0) 5.2 (3.8) 2.5 (1.0)
Somewhat dissatisﬁed 4.9 (1.2) 12.9 (4.1) 4.1 (1.2)
Very dissatisﬁed 5.3 (1.9) 2.2 (0.9) 5.6 (2.1)
Satisfaction with physical relationship
with partner (%)
Very satisﬁed 58.5 (3.3) 34.0 (6.9)*** 62.0 (3.5)
Somewhat satisﬁed 30.0 (3.0) 48.0 (8.0) 28.2 (3.2)
Neither 1.6 (0.5) 5.0 (3.0) 1.3 (0.4)
Somewhat dissatisﬁed 6.6 (1.6) 10.2 (3.2) 6.2 (1.8)
Very dissatisﬁed 3.2 (0.7) 12.8 (4.7) 2.2 (0.6)
†Statistical signiﬁcance designated as *P < 0.05; **P < 0.01; ***P < 0.001. There were no dif-
ferences by hypoactive sexual desire disorder (HSDD) status for: heart disease, high blood
pressure, high cholesterol, stroke or transient ischemic attack, heart attack, diabetes, obesity,
polycystic ovary syndrome, arthritis or joint pain, insomnia or sleep disturbances, thyroid
problems, urinary incontinence, osteoporosis, cancer other than breast or cervical, non-
cancerous breast lumps, breast cancer, cervical cancer, and headaches or migraines.
‡Standard errors are reported in parentheses.
§Removal of both ovaries (with or without concomitant hysterectomy) before natural
menopause.
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depression and antidepressant use. The interaction between
HSDD and surgical menopause was not statistically signiﬁcant
in any of the models and thus was eliminated from the model
speciﬁcation.
Health-Related Quality of Life Comparison by Age
Figure 1 shows SF-12 summary and domain scores for women
with HSDD compared with US norms by age for all women [29].
Survey results and norms for women ages 30–34 and 65–70
are not shown because of insufﬁcient numbers of women with
HSDD. Women with HSDD generally report lower scores for
both composites and all domain scores when compared with
the age-speciﬁc US norms for women. In results not shown, we
compared scores for women with HSDD to their age-matched
norm (i.e., women age 35–44 with HSDD vs. the US norms for
all woman age 35–44). For each age group, women with HSDD
reported greater impairment in all HRQOL domains than
the population-based norms. Women age 35–44 with HSDD
reported signiﬁcant impairment in physical aspects of HRQOL
(PCS-12, P = 0.008; GH, P = 0.011; PF, P = 0.002; RP,
P < 0.001; and BP, P < 0.001). Among women with HSDD age
45–54, the differences were statistically signiﬁcant for both
physical (PCS-12, P = 0.008; RP, P = 0.042; and BP, P < 0.001)
and emotional aspects of HRQOL (RE, P = 0.034 and MH,
P = 0.024). Only BP (P = 0.002) and MH (P = 0.010) attained
statistical signiﬁcance for women age 55–64 with HSDD. Similar
results were observed when comparing to Hanmer and
colleagues’ [36] age-based US population norms.
Health-Related Quality of Life Comparison between
HSDD and Selected Chronic Diseases
To place HSDD into context with other health conditions, we
compared the SF-12 scores of women with HSDD to available
norm scores for the general population (i.e., “healthy” popu-
lation without chronic disease) and for adults with various
chronic conditions (Fig. 2). Compared with the “healthy” popu-
lation, women with HSDD reported more HRQOL impair-
ments (all domains; P < 0.001). Although women with HSDD
reported fewer impairments in psychosocial aspects (MCS-12,
RE, MH, VT, SF; P < 0.001) than individuals with depre-
ssion, they were very similar in their report of physical im-
pairment and GH. Women with HSDD experienced similar
HRQOL when compared with individuals with back pain and
diabetes. Nevertheless, they did report better GH (P = 0.013)
and physical role functioning than individuals with diabetes
(P = 0.013).
Table 5 presents the mean, median, and quartiles for EQ-5D
scores of women with HSDD compared with conditions in
Sullivan and Ghushchyan’s [37] catalogue of nationally repre-
sentative, community-based preference scores. The norm value
Table 2 Differences in SF-12 mental and physical composite scores and domain scores for postmenopausal women† by HSDD and menopausal status
SF-12 scores HSDD No HSDD
Surgical menopause‡ Natural menopause
HSDD No HSDD HSDD No HSDD
Composites
PCS-12 45.0 (2.3) 47.3 (0.8) 44.6 (2.3) 45.1 (1.3) 45.6 (4.8) 48.8 (1.1)
MCS-12 47.3 (2.1)* 52.0 (0.6) 44.7 (2.1)* 50.6 (1.3) 51.1 (3.2) 53.0 (0.8)
Domains
GH 46.2 (1.9) 49.3 (0.8) 43.1 (2.3)* 48.9 (1.1) 50.6 (2.7) 49.6 (1.1)
PF 44.9 (2.1) 48.8 (0.8) 45.0 (2.3) 46.9 (1.2) 44.7 (3.8) 50.1 (1.0)
RP 46.4 (1.5) 47.6 (0.8) 45.7 (1.7) 45.6 (1.4) 47.5 (2.8) 49.0 (1.0)
RE 46.6 (1.7) 49.8 (0.7) 44.6 (2.6) 48.8 (1.0) 49.5 (1.4) 50.4 (1.0)
BP 41.4 (2.2)* 46.7 (0.9) 41.7 (2.7) 43.1 (1.4) 40.9 (3.5)* 49.2 (1.2)
MH 45.4 (1.9)** 51.0 (0.6) 43.1 (2.2)* 49.1 (1.0) 48.9 (2.7) 52.4 (0.8)
VT 47.7 (1.3)** 52.0 (0.7) 45.9 (1.6)* 50.2 (1.1) 50.2 (2.0) 53.3 (1.0)
SF 47.3 (1.4)* 50.9 (0.7) 45.5 (1.8) 48.6 (1.2) 49.7 (1.8) 52.5 (0.7)
Statistical signiﬁcance designated as *P < 0.05; **P < 0.01.
†Standard errors are reported in parentheses.
‡Removal of both ovaries (with or without concomitant hysterectomy) before natural menopause.
BP, bodily pain; GH, general health; HSDD, hypoactive sexual desire disorder; MCS-12, mental component summary score-SF-12; MH, mental health; PCS-12, physical component summary
score-SF-12; PF, physical functioning; RE, role emotional; RP, role physical; SF, social functioning; SF-12, Short Form 12;VT, vitality.
Table 3 Differences in EQ-5D. index scores and proportion† of postmenopausal women reporting difﬁculties with individual dimensions by HSDD and
menopausal status
EQ-5D HSDD No HSDD
Surgical menopause‡ Natural menopause
HSDD No HSDD HSDD No HSDD
Index score 0.76 (0.03)* 0.84 (0.02) 0.74 (0.04) 0.78 (0.04) 0.78 (0.03)** 0.88 (0.01)
Dimensions (% reporting any difﬁculty)
Mobility 45.4 (8.2) 31.2 (3.7) 44.5 (8.5) 38.6 (5.6) 46.7 (15.5) 26.1 (4.8)
Self-care 13.2 (5.2) 4.1 (2.1) 15.6 (7.2) 8.9 (4.9) 9.8 (6.8)*** 0.79 (0.34)
Usual activity 38.4 (8.3) 27.4 (3.5) 34.3 (8.0) 37.3 (5.6) 44.2 (15.6) 20.5 (4.3)
Pain/discomfort 70.3 (6.3)* 51.8 (3.8) 70.2 (7.4) 60.1 (5.5) 70.4 (11.0) 46.2 (5.2)
Anxiety/depression 47.8 (7.9)*** 21.7 (2.9) 45.1 (8.2) 29.8 (4.8) 51.6 (15.1)** 16.2 (3.6)
Statistical signiﬁcance designated as *P < 0.05; **P < 0.01; ***P < 0.001.
†Standard errors of mean and proportion are reported in parentheses.
‡Removal of both ovaries (with or without concomitant hysterectomy) before natural menopause.
EQ-5D, EuroQol 5-D index; HSDD, hypoactive sexual desire disorder.
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they report for menopausal disorder (International Classiﬁ-
cation of Disease, Ninth Clinical Modiﬁcation [ICD-9] 627)
of 0.817 is signiﬁcantly higher than the values we found
for women with HSDD (0.758), with the largest difference
observed compared with surgically menopausal women with
HSDD (0.745). Compared with women with other chronic
conditions, those with HSDD report similarly low EQ-5D
index scores.
Discussion
Our results offer a systematic evaluation of health status and
HRQOL in women with HSDD. Women with HSDD experi-
ence greater health burden in terms of comorbidities, and were
nearly twice as likely to report depression, fatigue, back pain,
and memory problems compared with women without HSDD.
They also reported poorer health status as reﬂected by lower
Table 4 Predictors of EQ-5D index and SF-12 composite (PCS-12 and MCS-12) scores in postmenopausal women
Characteristic
EQ-5D index PCS-12 MCS-12
B SE (B) B SE (B) B SE (B)
Constant 0.98 0.04 56.64 2.48 54.46 2.17
HSDD -0.07* 0.03 -1.64 2.14 -1.55 1.34
Surgical menopause -0.03* 0.02 -2.90** 1.08 -0.06 0.88
Current depressive symptoms and antidepressant use
No symptoms and not treated Reference category
No symptoms and treated -0.01 0.03 0.38 1.67 -4.72*** 1.06
Symptomatic and untreated -0.06* 0.03 1.06 1.94 -11.25*** 1.50
Symptomatic and treated -0.20*** 0.06 -6.90** 2.35 -14.47*** 2.26
Age
40–59 Reference category
50–59 -0.05 0.04 -1.41 1.86 -0.11 1.12
60–69 -0.01 0.02 -0.33 1.21 0.07 0.98
Race/ethnicity
White, non-Hispanic Reference category
Black, non-Hispanic 0.08** 0.03 2.80 2.31 0.06 2.31
Hispanic 0.00 0.04 -3.09 2.02 1.11 2.28
Other/multiracial -0.01 0.06 -4.73** 1.82 3.33* 1.55
Educational attainment
<High school/high school diploma Reference category
Vocational/2-year -0.03 0.03 2.36 1.68 1.81 1.21
4-year college degree -0.01 0.03 2.05 1.72 1.23 1.40
Graduate degree -0.02 0.03 2.02 1.83 1.95 1.41
Married or living together 0.04 0.03 1.08 1.62 0.30 1.20
Income $60,000 -0.01 0.02 0.15 1.12 -0.89 0.98
Current smoker -0.05* 0.02 -2.49* 1.15 -1.88 0.98
BMI
<25 Reference category
25-<30 0.01 0.02 -2.84* 1.29 1.44 1.05
30-<35 -0.01 0.03 -4.85* 1.90 1.65 1.30
35-<40 -0.01 0.03 -7.90*** 2.07 3.80** 1.38
40+ 0.02 0.04 -7.55** 2.29 2.42 1.95
Reported comorbidity
Cardiac -0.11* 0.05 -0.87 1.62 -2.49 1.92
Hypertension -0.01 0.02 -3.15** 1.18 -1.00 0.88
Hypercholesterolemia 0.01 0.02 -0.25 0.94 1.17 0.81
Diabetes -0.04 0.02 -5.09* 2.14 0.33 1.53
Thyroid condition 0.02 0.02 -1.52 1.45 0.05 1.18
Urinary incontinence -0.02 0.02 2.43* 1.22 -0.70 1.32
Osteoporosis 0.00 0.03 -3.65* 1.44 -0.43 1.03
Migraine -0.04 0.03 2.56* 1.15 -0.73 0.96
Fatigue 0.01 0.03 -4.67*** 1.16 -2.28* 1.09
Back pain -0.02 0.02 -2.33 1.24 -0.38 0.89
Arthritis -0.09*** 0.02 -3.64** 1.24 0.12 1.03
Insomnia 0.01 0.02 -0.37 1.12 1.56 0.90
Memory problems -0.06 0.03 -1.36 1.21 -1.26 0.96
Satisfaction with:
Home life: very satisﬁed Reference category
Home life: somewhat satisﬁed -0.02 0.02 -1.31 1.21 -3.64*** 1.06
Home life: dissatisﬁed -0.06 0.03 2.19 1.96 -3.92* 1.53
Emotion: very satisﬁed Reference category
Emotion: somewhat satisﬁed -0.02 0.02 -1.22 1.40 -1.02 1.05
Emotion: dissatisﬁed 0.04 0.04 3.97 3.10 0.10 1.80
Physical: very satisﬁed Reference category
Physical: somewhat satisﬁed 0.05* 0.02 2.34 1.12 0.42 1.06
Physical: dissatisﬁed 0.04 0.03 -2.63* 3.62 0.59 1.50
F 26.99 (P < 0.0001) 23.61 (P < 0.0001) 25.88 (P < 0.0001)
Adjusted R2 0.4955 0.4620 0.4858
Statistical signiﬁcance noted as: *P < 0.05; **P < 0.01; ***P < 0.001.
BMI, body mass index; Emotion, emotional relationship with partner; EQ-5D, EuroQol 5-D Index; HSDD, hypoactive sexual desire disorder; MCS-12, SF-12 mental health component summary
score; PCS-12, SF-12 physical health component summary score; Physical, physical relationship with partner; SE, standard error; SF-12, Short Form 12; Surgical menopause, removal of both ovaries
(with or without concomitant hysterectomy) before natural menopause.
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SF-12 scores with 4-point to 6-point differences in GH, BP,
MH, VT, and SF domain scores, and a 5-point difference
in the MCS-12 score. These differences generally persisted
after stratiﬁcation for menopausal status, with statistically
signiﬁcant differences observed for surgically menopausal
women. Differences for physical domains and summary scores
were on the order of 2 to 3 points, and were not statistically
signiﬁcant.
EQ-5D results present a similar pattern, reinforcing the
ﬁnding that women with HSDD have poorer quality of life than
women without. Women with HSDD reported signiﬁcantly lower
EQ-5D index scores than women without, experiencing a decre-
ment of 0.08 points (on a scale from 0 to 1), with a 0.1-point
decrement for naturally menopausal women with HSDD.
Women with HSDD reported more difﬁculties in general than
those without. They were 35% more likely to report pain and
discomfort and twice as likely to report pain and anxiety com-
pared with women without HSDD.
The availability of population-based norm scores for the
SF-12 [29,36] and the recent EQ-5D catalogue of preferences
scores [19,37] provide a context for evaluating the health burden
of HSDD. Compared with healthy adults without chronic dis-
eases, women with HSDD demonstrated signiﬁcantly poorer
HRQOL across all dimensions as measured by SF-12 scores. This
ﬁnding is not surprising given that women with HSDD were 10
years older (54 years vs. 44.8 years) and reported an average of
6.6 (vs. 5.1) chronic conditions compared with women without
HSDD. Women with HSDD reported similar proﬁles of impair-
ment when compared with the SF-12 norm scores for diabetes,
hypertension, back pain, and arthritis. These patterns are echoed
in the comparison of EQ-5D results with Sullivan and Ghush-
chyan’s [37] catalogue of EQ-5D index scores, with our score for
HSDD being signiﬁcantly lower than the estimate for meno-
pausal disorders (ICD-9 627) and comparable to various chronic
conditions.
In ﬁndings consistent with ours, Leiblum and colleagues
[8] report signiﬁcant decrements in HRQOL using data from
952 premenopausal and postmenopausal women. Reporting
un-normed SF-36 scores, which are neither comparable to
normed SF-12 scores or to the available norms for SF-36 scores
[29], they demonstrate that women with HSDD score con-
sistently lower (i.e., 5 to 16 points lower) on the eight SF-36
domains (summary scores are not reported), with smaller dif-
ferences for domains that capture aspects of physical health.
As well, our prevalence results [11] correspond to those
reported by Dennerstein and colleagues [9] and Leiblum and
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Figure 1 HRQOL comparisons between women
with HSDD and US norms for women by age.
For each age group (i.e., age 35–44, 45–54, 55–64),
women with HSDD reported greater impairment
in all HRQOL domains than the population-based
norms.Women age 35–44 with HSDD reported
signiﬁcant impairment in physical aspects of
HRQOL (PCS-12, P = 0.008; GH, P = 0.011; PF,
P = 0.002; RP, P < 0.001; and BP, P < 0.001). Among
women with HSDD age 45–54, the differences
were statistically signiﬁcant for both physical (PCS-
12, P = 0.008; RP, P = 0.042; and BP, P < 0.001)
and emotional aspects of HRQOL (RE, P = 0.034
and MH, P = 0.024). Only BP (P = 0.002) and MH
(P = 0.010) attained statistical signiﬁcance for
women age 55–64 with HSDD. Statistical signiﬁ-
cance designated as *P < 0.05; †P < 0.01; ‡P < 0.001.
BP, bodily pain; GH, general health; HRQOL,
health-related quality of life; HSDD, hypoactive
sexual desire disorder; MCS-12, mental compo-
nent summary score-SF-12; MH, mental health;
PCS-12, physical component summary score-SF-
12; PF, physical functioning; RE, role emotional; RP,
role physical; SF, social functioning; SF-12, Short
Form 12;VT, vitality.
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colleagues [8], which both used validated instruments of sexual
function and distress (i.e., the PFSF and PDS).
Our study design has several advantages over existing
research. First, our data come from a population-based survey
derived using a probability-sampling frame of US households
with telephone access, thus allowing us to make inferences at the
national level. Previous studies of sexual desire disorder have
employed clinical trial participants, small convenience samples,
or, in the case of the only study providing preliminary HRQOL
data, were derived from consumer marketing databases. Addi-
tionally, we assessed sexual desire and distress using instruments
that were validated in a postmenopausal population [22,23,28].
We also employed well-validated health status and HRQOL
instruments used extensively for population-based surveys of
various health conditions and calculated norm-based scores
[19,29–32,34,36,37,44,45]. By doing so, we were able to com-
pare our results directly with the population norms provided and
to provide nationally representative estimates of SF-12 and
EQ-5D index scores for HSDD.
Several limitations of our study should be noted. First, based
on the known prevalence of oophorectomy in young women,
we anticipated having difﬁculty identifying enough women age
30–39 years who had their ovaries removed. In addition,
although we had conducted an earlier pilot of our survey and
sampling approach, we had difﬁculty accruing the desired sample
size of women age 60–69 and had to modify our sampling
frequencies midsurvey. This modiﬁcation resulted in a ﬁnal
survey population that was heavily weighted towards women
50–59 years of age. In addition, we interviewed only 25% of the
women aged 60–70 that we had proposed, which affected our
power in analyses for this subgroup. In particular, we were
unable to compare SF-12 scores for women with HSDD ages
30–34 or 65–70 to age-speciﬁc population norms, and therefore
cannot draw with conﬁdence conclusions as to the comparative
severity of HSDD in these groups.
Second, telephone surveys although efﬁcient are subject to the
whims of technology; bias is a function of telephone coverage
and characteristics of nonrespondents. The advent of caller ID,
voicemail, and answering machines has contributed to declines in
telephone survey response rates [46]. During our survey period,
93.5% to 94% of households in the US had landline telephones
[47]. Individuals less likely to have a telephone include racial and
ethnic minorities, individuals with less education, who live in
rural areas, and who are more likely to report worse self-rated
health [48]. As well, renters and unemployed individuals are less
likely to have telephones [47,49,50]. The increase in cell phone
subscribership from 195 million to 207 million wireless tele-
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Figure 2 SF-12 score comparisons among women with HSDD, a healthy population, and adults with selected chronic diseases. Compared with the “healthy”
population, women with HSDD reported more HRQOL impairments (all domains; P < 0.001). Although women with HSDD reported fewer impairments in
psychosocial aspects (MCS-12, RE, MH,VT, SF; P < 0.001) than individuals with depression, they were very similar in their report of physical impairment and general
health.Women with HSDD experienced similar HRQOL when compared with individuals with back pain and diabetes. Nevertheless, they did report better general
health (P = 0.013) and physical role functioning than individuals with diabetes (P = 0.013). BP, bodily pain;GH, general health;Healthy = “healthy” adults with no chronic
conditions; HRQOL, health-related quality of life; HSDD, hypoactive sexual desire disorder; MCS-12, mental component summary score-SF-12; MH, mental health;
PCS-12, physical component summary score-SF-12; PF, physical functioning; RE, role emotional; RP, role physical; SF, social functioning; SF-12, Short Form 12;VT, vitality.
Table 5 Comparison of EQ-5D index scores for HSDD and selected
chronic conditions
Condition*
EQ-5D index score
Mean 25%ile Median 75%ile
HSDD 0.758 0.761 0.800 0.844
Surgically menopausal with HSDD 0.745 0.708 0.800 0.860
Naturally menopausal with HSDD 0.775 0.761 0.778 0.844
Angina pectoris (ICD-9 413) 0.695 0.517 0.768 0.827
Osteoarthritis (ICD-9 715) 0.703 0.689 0.778 0.816
Neurotic disorders (ICD-9 300) 0.739 0.506 0.778 0.844
Adjustment disorder (ICD-9 309) 0.739 0.597 0.800 0.844
Obesity (ICD-9 278) 0.744 0.708 0.800 0.844
Diabetes mellitus (ICD-9 250) 0.751 0.708 0.800 0.844
Gastritis and duodenitis (ICD-9 535) 0.765 0.708 0.800 0.844
Essential hypertension (ICD-9 401) 0.789 0.761 0.816 1.000
Asthma (ICD-9 493) 0.797 0.761 0.827 1.000
Breast cancer (ICD-9 174) 0.803 0.708 0.816 1.000
Migraine (ICD-9 346) 0.806 0.778 0.827 1.000
Menopausal disorders (ICD-9 627) 0.817 0.778 0.827 1.000
Acquired hypothyroidism (ICD-9 244) 0.821 0.778 0.827 1.000
Benign mammary dysplasia (ICD-9 610) 0.852 0.810 0.827 1.000
*Data for conditions other than HSDD obtained from Sullivan and Ghushchyan [37].
EQ-5D, EuroQoL 5-D; HSDD, hypoactive sexual desire disorder; ICD-9, International Clas-
siﬁcation of Diseases-Ninth Clinical Modiﬁcation; 25%ile, 25th percentile (i.e., lower quartile);
75%ile, 75th percentile (i.e., upper quartile).
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phones in use in 2005 [47] also may result in bias. Studies suggest
that the cell phone only group is demographically distinct from
individuals with landlines [46]. These individuals are either
young (age 18–30), relatively wealthy renters, or poor ethnic
minorities who have cell phones for economic reasons [47,51].
Surveys, including ours, are typically weighted to account for
nonresponse from landline coverage [52,53]; reweighting for cell
phone coverage has been suggested but is not commonly imple-
mented [54]. Blumberg et al. [54] further has suggested that
excluding these individuals may not result in large bias and has
shown that they generally resemble individuals with landlines in
terms of health-risk behaviors.
As well, our survey response rate (56.7%) was somewhat
lower than the rates reported by other studies evaluating sexual
function in women; differences may be due to the sample selected
and survey administration approach. Dennerstein and Lehert
[54] reported a rate of 71% from a convenience sample of
women recruited through their physicians, ofﬁces; the women
also completed written questionnaires. Leiblum and colleagues
[8] employed a mail survey (77% response) of women selected
from a marketing research pool. These women may have been
more likely to respond to surveys in general than the women who
participated in our national telephone survey. Differences in
survey administration may account for our lower response rate.
Our response rate, however, was similar to that of the 2004
Behavioral Risk Factor Surveillance System (BRFSS) (median
response rate 47.2%), which asks data about sensitive topics,
including HIV testing, drug use, and binge drinking. Recent
studies suggest that the BRFSS yields results that are similar to
those of national in-person surveys such as the National Health
Interview Survey and National Health and Nutrition Surveys,
which have higher response rates [55,56]. We were unable to
collect any data from nonresponders in the current study because
of institutional review board restrictions and thus do not know
whether women who declined to participate in the survey were
systematically different from women who did participate in the
survey. As well, we are unable to determine whether non-
responders were similar to individuals who typically do not
respond to surveys.
An additional concern is that the PFSF and PDS instruments
were validated for self-administration, whereas, in our study,
the instrument was administered by a female interviewer. It is
unclear whether this difference changed how women answered
the questions. Nevertheless, when we compared our results
to those of Leiblum and colleagues [8] who used self-
administration of the PFSF and the PDS, we saw little differ-
ence when evaluating the correlations across the sexual interest,
arousal, and orgasm domains [11]. In addition, the prevalence
of HSDD was similar between the two studies. Thus, we
feel that mode of administration did not affect our survey
results.
Conclusions
Using a nationally representative sample, this study shows that
postmenopausal women with HSDD report poorer health status
and HRQOL than women without HSDD. These impairments,
though apparent in all aspects of quality of life, are particularly
pronounced for BP and MH and psychosocial aspects of quality
of life, including SF and VT. When compared with national
norms, our results indicate a degree of impairment comparable to
that observed for common chronic conditions such as hyperten-
sion, diabetes, osteoarthritis, and asthma. Given recent estimates
of the prevalence of HSDD [8,11], HSDD affects a signiﬁcant
number of women [11]. Taken together, these results suggest that
HSDD represents a signiﬁcant and clinically relevant problem
rather than a disorder “medicalised” for its pharmaceutical
market potential.
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